Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec 1;45(21):12469-12480.
doi: 10.1093/nar/gkx902.

The MRPP1/MRPP2 complex is a tRNA-maturation platform in human mitochondria

Affiliations

The MRPP1/MRPP2 complex is a tRNA-maturation platform in human mitochondria

Linda Reinhard et al. Nucleic Acids Res. .

Abstract

Mitochondrial polycistronic transcripts are extensively processed to give rise to functional mRNAs, rRNAs and tRNAs; starting with the release of tRNA elements through 5'-processing by RNase P (MRPP1/2/3-complex) and 3'-processing by RNase Z (ELAC2). Here, we show using in vitro experiments that MRPP1/2 is not only a component of the mitochondrial RNase P but that it retains the tRNA product from the 5'-processing step and significantly enhances the efficiency of ELAC2-catalyzed 3'-processing for 17 of the 22 tRNAs encoded in the human mitochondrial genome. Furthermore, MRPP1/2 retains the tRNA product after ELAC2 processing and presents the nascent tRNA to the mitochondrial CCA-adding enzyme. Thus, in addition to being an essential component of the RNase P reaction, MRPP1/2 serves as a processing platform for several down-stream tRNA maturation steps in human mitochondria. These findings are of fundamental importance for our molecular understanding of disease-related mutations in MRPP1/2, ELAC2 and mitochondrial tRNA genes.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Role of MRPP1/2 in RNase P function on tRNATyr. (A) Schematic representation of the light-strand (LS) tRNA cluster Tyr-Cys-Asn-Ala and its complementary heavy-strand (HS). (B) Secondary structure of human pre-tRNATyr(38,17) (Y(38,17)) having 38 nt as 5′-leader and 17 nt as 3′-trailer. The discriminator base is boxed. (C) RNase P dilution series on 200 nM tRNATyr(38,17). Top: MRPP3 dilution (from 800 to 3.1 nM) and MRPP1/2 constant (800 nM). Bottom: MRPP1/2 dilution (from 800 to 3.1 nM) and MRPP3 constant (50 nM). The molar ratio of tRNA to protein is given in brackets. The reactions were incubated for 1 h. (DF) Gel filtration chromatograms of MRPP1/2:pre-tRNATyr(5,6) prior and after MRPP3 treatment as well as of MRPP3 alone (D). Peaks of interest are numbered and the peaks tRNA and protein content are visualized by urea PAGE (E) and SDS-PAGE (F), respectively.
Figure 2.
Figure 2.
Role of MRPP1/2 in RNase P function on tRNAHis. (A) Schematic representation of the heavy-strand (HS) tRNA cluster His-Ser(AGY)-Leu(CUN). The 5′- and 3′-region of tRNAHis (in black) are highlighted in red and blue, respectively. (B) Secondary structure of pre-tRNAHis(25,tRNASer(AGY)) (H(25,S)) having 25 nt as 5′-leader (in red) and the complete tRNASer(AGY) as 3′-trailer (in blue). The discriminator bases are boxed. (C) RNase P dilution series on 200 nM tRNAHis(25,S). Top: MRPP3 dilution (from 800 to 3.1 nM) and MRPP1/2 constant (800 nM). Bottom: MRPP1/2 dilution (from 800 to 3.1 nM) and MRPP3 constant (50 nM). The molar ratio of tRNA to protein is shown in parentheses. The reactions were incubated for 1 h. (DF) Gel filtration chromatograms of MRPP1/2:pre-tRNAHis(25,S) prior and after MRPP3 treatment (D). Peaks of interest are numbered, and tRNA and protein content of the peaks are visualized by urea PAGE (E) and SDS-PAGE (F), respectively.
Figure 3.
Figure 3.
MRPP1/2 supports ELAC2 based 3′-tail removal. (A and B) ELAC2 activity in the absence and presence of 800 nM MRPP1/2 at different salt concentrations (15–200 mM KCl) on pre-tRNATyr(0,17) (Y(0,17)) (A) and pre-tRNAHis(0,S) (H(0,S)) (B). Mis-cleavage on Y(0,17) is indicated by asterisks. The reaction mixes of H(0,S) were incubated for 1 h.
Figure 4.
Figure 4.
Role of MRPP1/2 in RNase Z function on tRNATyr and tRNAHis. (A) RNase Z dilution experiments on pre-tRNATyr(0,17) (Y(0,17)). Top: ELAC2 dilution series (800–3.1 nM) in the presence of 800 nM MRPP1/2. Middle: MRPP1/2 dilution series (800–3.1 nM) in the presence of 50 nM ELAC2. Bottom: ELAC2 dilution series (800–3.1 nM) in the absence of MRPP1/2. The reactions were incubated for 1 h. The molar ratio of tRNA to protein is shown in parentheses. (BD) Gel filtration chromatograms of MRPP1/2:pre-tRNATyr(5,6) after treatment with MRPP3 and ELAC2, as well as of MRPP3 and ELAC2 alone. Peaks of interest are numbered and tRNA and protein content of the peaks is visualized by urea PAGE (C) and SDS-PAGE (D), respectively. For comparison, also pre-tRNATyr(5,6) and pre-tRNATyr(0,6) from Figure 1E are shown in (C). (E) RNase Z dilution experiments on pre-tRNAHis(0,S) (H(0,S)). Reaction condition are as given in (A). (FH) Gel filtration chromatograms of MRPP1/2:pre-tRNAHis(0,S) prior to and after treatment with ELAC2. Peaks of interest are numbered, and tRNA and protein content of the peaks is visualized by urea PAGE (G) and SDS-PAGE (H), respectively.
Figure 5.
Figure 5.
Mitochondrial tRNA processing order and CCA-adding enzyme modify MRPP1/2 bound tRNA. (A and B) Processing order of RNase P and RNase Z on pre-tRNATyr (38,17) (Y (38,17)) (A) and pre-tRNAHis(25,S) (H(25,S)) (B). For activity measurements, 800 nM MRPP1/2, 50 nM MRPP3 and 50 nM ELAC2, or combinations, were used. (C and D) Activity of CCA-adding enzyme (CCA-E, 50 nM) on pre-tRNATyr(0,0) (Y(0,0)) (C) and pre-tRNAHis(0,0) (H(0,0)) (D) in the absence and presence of 800 nM MRPP1/2. Hyper-modified tRNA is indicated by asterisks. (EG) Gel filtration chromatograms of MRPP1/2:pre-tRNATyr(0,0) after incubation with CCA-adding enzyme and rNTPs (E). Peaks of interested are numbered, and tRNA and protein content of the peaks is visualized by urea PAGE (F) and SDS-PAGE (G), respectively.

Similar articles

Cited by

References

    1. Hällberg B.M., Larsson N.G.. Making proteins in the powerhouse. Cell Metab. 2014; 20:226–240. - PubMed
    1. Kauppila T.E., Kauppila J.H., Larsson N.G.. Mammalian mitochondria and aging: an update. Cell Metab. 2017; 25:57–71. - PubMed
    1. Brown T.A., Tkachuk A.N., Shtengel G., Kopek B.G., Bogenhagen D.F., Hess H.F., Clayton D.A.. Superresolution fluorescence imaging of mitochondrial nucleoids reveals their spatial range, limits, and membrane interaction. Mol. Cell. Biol. 2011; 31:4994–5010. - PMC - PubMed
    1. Kukat C., Wurm C.A., Spåhr H., Falkenberg M., Larsson N.G., Jakobs S.. Super-resolution microscopy reveals that mammalian mitochondrial nucleoids have a uniform size and frequently contain a single copy of mtDNA. Proc. Natl. Acad. Sci. U.S.A. 2011; 108:13534–13539. - PMC - PubMed
    1. Anderson S., Bankier A.T., Barrell B.G., de Bruijn M.H., Coulson A.R., Drouin J., Eperon I.C., Nierlich D.P., Roe B.A., Sanger F. et al. . Sequence and organization of the human mitochondrial genome. Nature. 1981; 290:457–465. - PubMed

MeSH terms